All In Biotech

NDA 215960 · Glaxosmithkline

Utebzi

Tebipenem Pivoxil Hydrobromide · Oral

NovelPriority review

CDER novel approval, Jun 17, 2026: To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jun 17, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

11

2 Phase 3, 0 recruiting

FAERS reports

6

5 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 17, 2026.

UTEBZI is a penem antibacterial indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca , and Enterococcus faecalis in adult patients who have limited or no alternative oral treatment options. ( 1.1 ) Usage to Reduce Development of Drug ‑ Resistant Bacteria To reduce the development of drug‑resistant bacteria and maintain the effectiveness of UTEBZI and other antibacterial drugs, UTEBZI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infection (cUTI), Including Pyelonephritis UTEBZI is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae species complex, Klebsiella oxytoca , and Enterococcus faecalis in adult patients who have limited or no alternative oral treatment options. 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug‑resistant bacteria and maintain the effectiveness of UTEBZI and other antibacterial drugs, UTEBZI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Tebipenem pivoxil is a prodrug of tebipenem, an antibacterial drug [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 17, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • UTEBZI · TEBIPENEM PIVOXIL HYDROBROMIDE EQ 300MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tebipenem Pivoxil Hydrobromide" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction2
  • nausea2
  • anticonvulsant drug level below therapeutic1
  • bacterial pyelonephritis1
  • blood lactic acid increased1
  • cholangitis1
  • clostridium difficile infection1
  • coagulopathy1
  • disseminated intravascular coagulation1
  • drug level decreased1
  • epilepsy1
  • fatigue1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20153
20171
20211
20221

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.